Oslo, Norway, 26 April 2010

Photocure ASA will present its first quarter 2010 report on Wednesday April
28(th) 2010 at Shippingklubben, Haakon VIIs gate 1 (top floor), Oslo, Norway.

The presentation will begin at 17.00 and representatives from the company will
be Kjetil Hestdal (President & CEO) and Christian Fekete (CFO).

The presentation is scheduled to conclude at 17.45 (CET).

The presentation will be publicly available atwww.photocure.com
. It will be possible to follow the presentation
through a live webcast at
Photocure's Internet pages.

Please register your attendance at Photocure ASA by Tuesday 27(th) of April at
15:00. Contact person: Grete Faye-Schjøll (e-mail: gfs@photocure.no
/ phone +47 22 06 22 10 / fax +47 22 06 22 18).

About Photocure

Photocure is a Norwegian pharmaceutical company listed on the Oslo Stock
Exchange (OSE: PHO). The company develops and sells pharmaceuticals and medical
devices for the photodynamic treatment and diagnosis of cancer and selected
dermatology indications.

Photocure's commercial activities includes own marketing and sales in selected
markets as well as out-licensing on a regional or global basis prior to phase
III.

Photocure has one proprietary pharmaceutical product on the market: Hexvix(®),
for the diagnosis of bladder cancer. Hexvix is approved in EU. In addition, the
company has developed a proprietary light source, which is used in combination
with the Visonac(TM) cream. Through worldwide studies, Photocure is continuously
testing its products for new indications, and the aim is to develop a pipeline
of follow-on products based on the Photocure Technology(TM)platform.

For more information about Photocure, visit our website at www.photocure.com.

Photocure(®), the Photocure logo and Hexvix(®) are registered trademarks of
Photocure ASA.

This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)

[HUG#1408120]

Photocure ASA - Presentation of the 1st quarter 2010 report